The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure

Expert Opinion on Investigational Drugs

Volumn 22, Issue 8, 2013, Pages 1041-1047

  Voors, Adriaan A ^a   Dorhout, Bernard ^a   Van Der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE inhibitors; Angioedema; Heart failure; Hypertension; Neprilysin; Neutral endopeptidase inhibitors; Omapatrilat

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ENALAPRIL; LISINOPRIL; OMAPATRILAT; VALSARTAN;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; DRUG COMBINATIONS; HEART FAILURE; HUMANS; NEPRILYSIN; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 84880238450     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.797963     Document Type: Article

References (34)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. Task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69
2. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9
3. Voors AA, de Jong RM. Treating diastolic heart failure. Heart 2008;94:971-2
4. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47:320-32
5. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35
6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
7. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6
8. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
9. Pfeffer MA, Swedberg K, Granger CB, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003;362(9386):759-66; 1667-75
10. McMurray JJ, Ostergren J, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362(9386):767-71
11. van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: Controversial or common sense? Eur Heart J 2005;26:2361-7
12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
13. Zannad F, McMurray JJ, Krum H, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21
14. Krum H, Massie B, Abraham WT, et al. ATMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: Rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-14
15. McMurray JJ, Pitt B, Latini R, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24
16. Baran D, Horn EM, Hryniewicz K, Katz SD. Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure. Drugs 2000;60:997-1016
17. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8
18. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: Novel therapy for patients with cardiovascular disorders. Drugs 2003;63:2185-202
19. Cuculi F, Erne P. Combined neutral endopeptidase inhibitors. Expert Opin Investig Drugs 2011;20(4):457-63
20. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356(9230):615-20
21. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6
22. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-11
23. Segura J, Ruilope LM. Dual-acting angiotensin receptor-neprilysin inhibition. Curr Hypertens Rep 2011;13(1):74-8
24. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50:401-14
25. Baxter GF. The natriuretic peptides. Basic Res Cardiol 2004;99:71-5
26. Elmarakby AA, Morsing P, Pollock JS, Pollock DM. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats. Vascul Pharmacol 2003;40:253-9
27. Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-16
28. Gheorghiade M, Bohm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure. JAMA 2013;309(11):E1-E11
29. Freyer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: Rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-55
30. Timmermans PB, Smith RD. A new class of therapeutic agents: The angiotensin II receptor antagonists. Cardiologia 1994;39(Suppl 1):397-400
31. Waldmeier F, Flesch G, Müller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997;27:59-71
32. Ruilope LM, Dukat A, Bohm M, et al. Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomized, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-66
33. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95
34. McMurray JJV, Packer M, Desai AS, and on behalf of the PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: Rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; doi:10.1093/eurjhf/hft052